Vator Securities advises Magle Group on 27 MSEK Capital Raise
The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise, Magle PharmaCept – an established sales and marketing company for development and direct sales of the Group’s medical technology products and Magle Biopolymers A/S – a specialized manufacturing organization of Dextran technology.
The proceeds from the Directed Share Issue are intended to be used to advance key projects that reinforce Magle Group’s position in innovative medical solutions and support the group’s ongoing structural and organisational changes following recent mergers.
read more
Vator Securities advises Alligator Bioscience on 280 MSEK Capital Raise
Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer.
Its portfolio includes lead drug candidate mitazalimab, for which the company reported unprecedented survival data at 18-months follow up in first-line metastatic pancreatic cancer patients in Phase 2 testing and is in preparation for Phase 3 development.
read more
Vator Securities advises Magle Group on 37 MSEK Capital Raise
The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk.
Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise, Magle PharmaCept – an established sales and marketing company for development and direct sales of the Group’s medical technology products and Magle Biopolymers A/S – a specialized manufacturing organization of Dextran technology.
read more
Vator Securities advises Agtira on 60 MSEK Capital Raise
Agtira offers its Farming as a Service (FaaS) approach to food chains, shops and other stakeholders. This means that Agtira invests, builds and then operates its farming systems for the production of a range of vegetables and fish species, either by itself or together with a third party, while the store or chain undertakes to buy the entire volume produced over a certain contractual period at predetermined prices.
What Agtira’s farming systems have in common is that they produce food with low water consumption in closed environments, with no emissions to the local environment or need for agricultural land. Growing in urban environments also means reducing the need for transportation and reducing waste.
read more
27 MSEK | Q4 2024
280 MSEK | Q4 2024
37 MSEK | Q4 2024
60 MSEK | Q4 2024
